Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — Investor Presentation (2014)

22 slides from Sernova Biotherapeutics's investor presentation, 2014

  1. Slide 1: Sernova Corporate Presentation

    Slide 1: Sernova Corporate Presentation

    Founded 2006, London Ontario; TSX(v); SVA.V Sernova Corporate Presentation Philip Toleikis Ph.D., President and CEO 2014

  2. Slide 2: Cautionary and Forward-Looking Information

    Slide 2: Cautionary and Forward-Looking Information

    Sernova Corp Cautionary and Forward-Looking Information This presentation may contain forward looking statements. Forward looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipa

  3. Slide 3: Sernova Corp Company Overview

    Slide 3: Sernova Corp Company Overview

    Sernova Corp Company Overview A Regenerative medicine clinical stage Company Corporate London, Ontario Canada, Founded 2006; TSX(V): SVA.V Platform Technologies Cell Pouch ™ - Implantable medical device for therapeutic cells Therapeutic cells – Replace missing proteins or hormones; cells produce and

  4. Slide 4: Sernova's Therapeutic Goal: A Disruptive Approach to Treat Chronic Diseases

    Slide 4: Sernova's Therapeutic Goal: A Disruptive Approach to Treat Chronic Diseases

    Sernova’s Therapeutic Goal: A Disruptive Approach to Treat Chronic Diseases A Natural Cell Environment: Cell Pouch System™ Sernova An Unlimited Source of Safe Prevention of Therapeutic Cells Transplant Rejection: Sertolin™ Page 4

  5. Slide 5: Strong Patent Portfolio

    Slide 5: Strong Patent Portfolio

    Strong Patent Portfolio Over 20 issued and pending patents in 5 families: • Composition and use of medical devices for delivery and cell transplantation • Methods for predicting long-term therapeutic cell function • Use of sertoli and genetically modified sertoli cells for treatment of disease • Use

  6. Slide 6: Diabetes

    Slide 6: Diabetes

    Sernova’s Cell Pouch™ First Clinical Indication Diabetes Page 6

  7. Slide 7: Cell Pouch System: Diabetes Market Potential

    Slide 7: Cell Pouch System: Diabetes Market Potential

    Cell Pouch System™: Diabetes Market Potential Diabetes Market Diabetes Epidemiology* 27% Type 1 Insulin-dependent (10%) 10% Type 2 Insulin-resistant (63%) Type 2 Insulin-dependent; (27%) 63% Insulin therapy: 37% (9M US/34M Asia) US Market 23.6M Patients Diabetes side effects: heart, kidney, nerve di

  8. Slide 8: Current Diabetes Treatments Are Inadequate

    Slide 8: Current Diabetes Treatments Are Inadequate

    Current Diabetes Treatments Are Inadequate Artificial management of blood glucose • Solution Insulin injections, pumps, etc. • Benefits Readily available; treatment relatively inexpensive • Issues Low patient QOL Insulin levels spike and decay, poor compliance serious side effects No improvement in

  9. Slide 9: Insulin Pumps — a huge unmet medical need

    Slide 9: Insulin Pumps — a huge unmet medical need

    Current “State of the Art” in Diabetes Management: Insulin Pumps — a huge unmet medical Need Components, clockwise include: Insulin; Insulin pump reservoir AAA battery Insulin pump infusion set Emergency glucagon kit Insulin pump Test strips Lancets z Typical approximate annual cost (U.S.): with ins

  10. Slide 10: The Current Approach to Islet Transplantation: The Edmonton Protocol

    Slide 10: The Current Approach to Islet Transplantation: The Edmonton Protocol

    The Current Approach to Islet Transplantation: The Edmonton Protocol Treatment of hypoglycemia unawareness with potential for insulin independence Portal vein islet transplantation; lifelong immunosuppression A study of 36 patients using the Edmonton Protocol Improvement in hypoglycemia unawareness

  11. Slide 11: Sernova: Improving Islet Transplantation Standard of Care

    Slide 11: Sernova: Improving Islet Transplantation Standard of Care

    Sernova: Improving Islet Transplantation Standard of Care Edmonton Protocol Cell Pouch System™ Catherization laboratory Surgical outpatient Intrahepatic site Extrahepatic site Loss of 60-75% of islets immediately-IBMIR No IBMIR Portal hypertension, thrombosis No Portal hypertension or thrombosis Isl

  12. Slide 12: Cell Pouch Preclinical Summary

    Slide 12: Cell Pouch Preclinical Summary

    Cell Pouch™ Preclinical Summary Cell Pouch™ contract manufactured (ISO 13485) Cell Pouch™ is biocompatible (ISO 10993 studies) Safety confirmed in 4 animal models rodent, pig, non-human primate Efficacy Confirmed: isograft, autograft, allograft diabetes models Sertoli cells protect therapeutic cells

  13. Slide 13: Successful Preclinical Results: Cell Pouch Islet Transplant

    Slide 13: Successful Preclinical Results: Cell Pouch Islet Transplant

    Successful Preclinical Results: Cell Pouch™ Islet Transplant Rodent Transplant Proof of Cell Pouch™ Microvessel Development

  14. Slide 14: Cell Pouch: Autografts Preclinical Human Product Diabetes Efficacy

    Slide 14: Cell Pouch: Autografts Preclinical Human Product Diabetes Efficacy

    8 Wks Post Cell Pouch™Implant Cell Pouch™: Porcine AutograftsPreclinical Human Product Diabetes Efficacy Cell Pouch™ developed tissue chambers rich in Healthy Islets in the Cell Pouch™ (purple); microvessels microvessels for cell transplant (red arrows) (12 weeks post transplant) Implanted Cell Pouc

  15. Slide 15: Sertolin: Successful Local Islet Immune Protection

    Slide 15: Sertolin: Successful Local Islet Immune Protection

    Sertolin™: Successful Local Islet Immune Protection Sertoli/Islets Islets Alone A B Natural immune-privileged Day 7 environment protecting cells from immune destruction eliminating the need for C D systemic anti-rejection protocols Day 21 Porcine islets and sertoli cells in diabetic mice Page 15 Arr

  16. Slide 16: Phase I/II Study of Safety and Efficacy of Cell Pouch

    Slide 16: Phase I/II Study of Safety and Efficacy of Cell Pouch

    A Phase I/II Study of the Safety and Efficacy of Sernova’s Cell Pouch™ for Therapeutic Islet Transplantation Principal Investigator: A.M. James Shapiro, M.D., Ph.D., FRCS (Eng), FRCSC www.islet.ca www.clinical trials.gov Page 16

  17. Slide 17: Sernova's Cell Pouch Phase I/II Clinical Study

    Slide 17: Sernova's Cell Pouch Phase I/II Clinical Study

    Sernova’s Cell Pouch™ Phase I/II Clinical Study Principal Investigator: Dr. A. J. Shapiro (Developer of Edmonton Protocol; U. Alberta) Study Design Patients with unstable diabetes Cell Pouch™ implant followed by donor islet transplantation Immunosuppression Standard current Edmonton approach (alemtu

  18. Slide 18: Positive Interim Safety Results

    Slide 18: Positive Interim Safety Results

    Positive Interim Safety Results Presented by Dr. James Shapiro at the International Pancreas and Islet Transplantation Association World Congress, 2013 Primary endpoint Cell Pouch™ Safety First patients Cell Pouches™ successfully implanted under the skin patients met the Primary Endpoint of Safety p

  19. Slide 19: Encouraging Early Time Point Results in the First Patients Treated

    Slide 19: Encouraging Early Time Point Results in the First Patients Treated

    Encouraging Early Time Point Results in the First Patients Treated Clear histological evidence of vascularized islet survival in both cases, up to one month No inflammatory cell destruction of islets; antirejection therapy protected islets Proof of islets making insulin, glucagon, and somatostatin;

  20. Slide 20: Haemophilia: Sernova Corp/Medicyte GMBH Product Development Collaboration

    Slide 20: Haemophilia: Sernova Corp/Medicyte GMBH Product Development Collaboration

    Haemophilia: Sernova Corp/Medicyte GMBH Product Development Collaboration Haemophilia A - prolonged bleeding due to absence of Factor VIII Current therapy - Factor VIII infusions 3x weekly at ≈ $260K/yr/patient for prophylactic therapy; a multi billion dollar opportunity Effects of inadequate treatm

  21. Slide 21: Management Team and BOD

    Slide 21: Management Team and BOD

    Management Team and BOD Core Executive Management President & CEO - Dr. Philip Toleikis, BA., MSc., Ph.D. Joined 2009; Pharmaceutical/Device Consultant, V.P. R&D Pharmacology, Angiotech Pharmaceuticals (1996-2006) Sr. Director R&D – Delfina Mazzuca-Siroen, BSc. Hon. Biochem., MSc. >20 yrs. R&D Mgmt.

  22. Slide 22: Corporate Presentation

    Slide 22: Corporate Presentation

    Founded 2006, London Ontario; TSX(v); SVA.V Corporate Presentation Philip Toleikis Ph.D., President and CEO 2014

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks